Aims
Diabetic retinopathy (DR) is a significant global public health concern. Alternative, safe, and cost-effective pharmacologic approaches are warranted. We aimed to investigate the therapeutic potential of nattokinase (NK) for early DR and the underlying molecular mechanism.
Conclusions
This study demonstrated the protective effects of NK against microvascular damages and neuroinflammation in the streptozotocin-induced DR model, suggesting that NK could be a potential pharmaceutical agent for the treatment of DR. 目的: 糖尿病视网膜病变（DR）是一个重要的全球公共卫生问题。需要寻求安全、有效且经济的替代性药物治疗方案。本研究的目的是探讨纳豆激酶（NK）对早期DR的治疗潜力及其潜在的分子机制。 方法: 使用链脲佐啶诱导的糖尿病小鼠模型，通过玻璃体腔内注射给予NK。通过检查血液视网膜屏障功能障碍导致的渗漏和毛细血管周细胞丢失来评估微血管异常。通过评估胶质细胞活化和白细胞粘附来评估视网膜神经炎症。在NK处理后，评估高迁移率族蛋白B1（HMGB1）及其下游信号分子的水平。 结果: NK处理显著改善了糖尿病大鼠血-视网膜屏障功能并逆转了糖尿病视网膜中毛细血管周细胞的丢失。此外，NK处理抑制了糖尿病诱导的胶质细胞活化和炎症反应，并保护视网膜神经元免受糖尿病损伤。NK还改善了高糖诱导的人视网膜微血管内皮细胞功能障碍。在机制上，NK通过调节活化的小胶质细胞中的HMGB1信号，部分调节糖尿病诱导的炎症。 结论: 本研究表明，NK对链脲佐啶诱导的DR模型中的微血管损伤和神经炎症具有保护作用，这表明NK可能是治疗DR的潜在药物。.
Methods
A mouse model of diabetes induced by streptozotocin was utilized and NK was administered via intravitreal injection. Microvascular abnormities were evaluated by examining the leakage from blood-retinal barrier dysfunction and loss of pericytes. Retinal neuroinflammation was examined through the assessment of glial activation and leukostasis. The level of high mobility group box 1 (HMGB1) and its downstream signaling molecules was evaluated following NK treatment.
Results
NK administration significantly improved the blood-retinal barrier function and rescued pericyte loss in the diabetic retinas. Additionally, NK treatment inhibited diabetes-induced gliosis and inflammatory response and protected retinal neurons from diabetes-induced injury. NK also improved high glucose-induced dysfunction in cultured human retinal micrangium endothelial cells. Mechanistically, NK regulated diabetes-induced inflammation partially by modulating HMGB1 signaling in the activated microglia. Conclusions: This study demonstrated the protective effects of NK against microvascular damages and neuroinflammation in the streptozotocin-induced DR model, suggesting that NK could be a potential pharmaceutical agent for the treatment of DR. 目的: 糖尿病视网膜病变（DR）是一个重要的全球公共卫生问题。需要寻求安全、有效且经济的替代性药物治疗方案。本研究的目的是探讨纳豆激酶（NK）对早期DR的治疗潜力及其潜在的分子机制。 方法: 使用链脲佐啶诱导的糖尿病小鼠模型，通过玻璃体腔内注射给予NK。通过检查血液视网膜屏障功能障碍导致的渗漏和毛细血管周细胞丢失来评估微血管异常。通过评估胶质细胞活化和白细胞粘附来评估视网膜神经炎症。在NK处理后，评估高迁移率族蛋白B1（HMGB1）及其下游信号分子的水平。 结果: NK处理显著改善了糖尿病大鼠血-视网膜屏障功能并逆转了糖尿病视网膜中毛细血管周细胞的丢失。此外，NK处理抑制了糖尿病诱导的胶质细胞活化和炎症反应，并保护视网膜神经元免受糖尿病损伤。NK还改善了高糖诱导的人视网膜微血管内皮细胞功能障碍。在机制上，NK通过调节活化的小胶质细胞中的HMGB1信号，部分调节糖尿病诱导的炎症。 结论: 本研究表明，NK对链脲佐啶诱导的DR模型中的微血管损伤和神经炎症具有保护作用，这表明NK可能是治疗DR的潜在药物。.